Van K. Morris, MD

Articles

Dr. Morris on the Design of the COBRA Trial in Stage II Colon Cancer

September 8th 2020

Van K. Morris, MD, discusses the design of the prospective phase 2/3 NRG-GI005 (COBRA) trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with colon cancer.

Dr. Morris on the Role of Circulating Tumor DNA in Resected Colon Cancer

August 27th 2020

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

May 20th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

May 19th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Dr. Morris on Treatment Advances Made in BRAF-Mutated mCRC

February 25th 2020

Van K. Morris, MD, discusses the recent progress made in the treatment of patients with BRAF-mutated metastatic colorectal cancer.

Dr. Morris on Optimizing CRC Treatment Based on Oligometastatic Status

January 25th 2020

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.

Dr. Van Morris on Nivolumab as a Potential Treatment for Patients With Anal Cancer

May 2nd 2016

Van K. Morris, MD, assistant professor of GI Oncology, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) as a potential treatment for patients with anal cancer.